No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Advanced Medical Solutions reported record full-year revenue and adjusted earnings for 2025 on Wednesday, driven by strong organic growth and the full-year contribution from recent acquisitions, as the group signalled continued momentum into 2026.
The AIM-traded tissue-healing specialist said group revenue rose 29% to 228.9m for the year ended 31 December, up from 177.5m, supported by the first full-year impact of the Peters Surgical acquisition and continued growth across key product categories.
On a constant currency basis, the existing business delivered 10% growth.
Adjusted EBITDA increased 24% to 49.9m, although the margin edged lower to 21.8% from 22.6%, while adjusted profit before tax rose 15% to 33.9m.
Reported profit before tax increased 81% to 17.8m, reflecting operational leverage and acquisition contributions.
Adjusted diluted earnings per share rose 12% to 11.74p.
The Surgical business remained the primary growth driver, with revenue rising 36% to 183.5m at constant currency.
Within that, LiquiBand revenue grew 10% to 47.8m, biosurgical devices increased 23% to 27.8m, and suture, clips and vascular temporary occlusion products surged 64% to 82.7m.
The Advanced Woundcare division returned to growth, with revenue up 9% to 45.5m.
Net operating cash flow rose 67% to 32.6m, while net debt reduced to 50.5m from 55.8m, despite ongoing investment in manufacturing transformation and integration activities.
"I am proud to report that we have delivered on our key strategic objectives for 2025," said chief executive Chris Meredith.
"The strength of our expanded portfolio, our growing global presence, and the commercial synergies across the group, have all contributed to another year of robust growth.
"This strong performance has enabled us to increase our dividend for the year by 10%."
He added that integration of recent acquisitions was progressing well, with commercial synergies already contributing to growth and operational synergies on track.
"Our robust and advancing R&D pipeline reinforces our confidence in carrying this momentum forward," he said.
The board proposed a full-year dividend of 2.86p per share, up 10% from 2.60p, reflecting confidence in the group's outlook.
Operationally, the group said it continued to realise synergies from the acquisitions of Peters Surgical and Syntacoll, including expanding direct sales channels and increasing penetration of key products such as LiquiBand XL and Ifabond.
The company also highlighted a strong innovation pipeline, with multiple product approvals expected from 2026 across adhesives, sutures and collagen technologies.
Looking ahead, AMS said it expected continued strong growth in its Surgical division and modest growth in Woundcare, supported by long-term supply agreements and ongoing product traction.
The board said it expected 2026 revenue and adjusted EBITDA to be in line with current market expectations, underpinned by strong cash generation and disciplined capital allocation.
At 1142 GMT, shares in Advanced Medical Solutions Group were up 2.39% at 201.5p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate